The patient's own body becomes the medicine
No final de 2023, o Brasil deu mais um passo em direção à medicina personalizada ao aprovar o TECARTUS, uma terapia gênica que transforma as próprias células imunológicas do paciente em agentes anticancerígenos. A aprovação pela Anvisa — a quarta do tipo no país — abre caminho para adultos com linfoma de células do manto ou leucemia linfoblástica aguda que já esgotaram as opções convencionais. É um momento que reflete tanto o avanço da ciência quanto a persistência humana diante de doenças que, até pouco tempo atrás, deixavam pouquíssimas saídas.
- Pacientes com linfoma agressivo e sem resposta a tratamentos anteriores enfrentavam um beco sem saída — agora, pela primeira vez no Brasil, há uma terapia aprovada especificamente para eles.
- O processo exige que as células do paciente sejam enviadas ao exterior para modificação genética, criando uma cadeia logística complexa e dependente de infraestrutura internacional.
- A tecnologia CAR-T reprograma linfócitos T para reconhecer e destruir células cancerígenas com precisão, funcionando como um sistema imunológico sob medida.
- Com quatro terapias gênicas avançadas aprovadas, o Brasil sinaliza uma abertura crescente a tratamentos de ponta, ainda que o acesso amplo permaneça um desafio estrutural.
No fim de 2023, a Anvisa aprovou o TECARTUS, desenvolvido pela Kite, tornando-o a quarta terapia CAR-T autorizada no Brasil. O medicamento é indicado para adultos com linfoma de células do manto — uma forma rara e agressiva de linfoma não-Hodgkin — e para pacientes com leucemia linfoblástica aguda que não responderam ou tiveram recaída após pelo menos dois tratamentos convencionais.
O funcionamento da terapia é ao mesmo tempo sofisticado e intuitivo: células T são extraídas do próprio paciente e enviadas a laboratórios especializados no exterior, onde recebem uma modificação genética que as equipa com receptores quiméricos de antígeno — as proteínas CAR. Esses receptores ensinam as células a identificar e destruir o CD19, uma proteína presente na superfície das células cancerígenas. Depois de modificadas, as células retornam ao paciente por infusão. O corpo, em essência, torna-se o próprio remédio.
O que distingue essa abordagem é sua natureza personalizada: cada tratamento é construído a partir das células de uma única pessoa, funcionando como uma imunoterapia sob medida. Para quem já esgotou as alternativas disponíveis, a aprovação representa uma porta que antes simplesmente não existia no país — ainda que percorrê-la exija tempo, logística internacional e infraestrutura especializada.
Late in 2023, Brazil's health regulator Anvisa cleared a new cancer treatment built on a deceptively simple idea: take a patient's own immune cells, reprogram them in a laboratory, and send them back to fight the disease. The drug is called TECARTUS, made by Kite, and it represents the fourth gene therapy of its kind to win approval in the country.
The treatment targets mantle cell lymphoma, an aggressive form of non-Hodgkin's lymphoma that arises from abnormal B lymphocytes. It is a rare cancer, and until now, Brazil had no approved therapy of this advanced type specifically for it. TECARTUS is indicated for adults whose disease has returned after previous treatment or who never responded to at least two rounds of conventional therapy. The same drug also won approval for acute lymphoblastic leukemia in patients facing similar circumstances—disease that has come back or refused to budge despite earlier interventions.
The mechanism is elegant in concept but logistically complex in practice. Doctors extract T cells from the patient's own immune system. These cells are then transported to a specialized facility—all of which, for now, operate outside Brazil. There, technicians perform genetic modification to equip each T cell with a new protein called a chimeric antigen receptor, or CAR. This engineered receptor acts as a homing device and weapon combined: it teaches the T cell to recognize CD19, a protein that sits on the surface of cancer cells, and to destroy them on contact. Once modified, the cells are shipped back and infused into the patient. In effect, the patient's own body becomes the medicine.
What makes this approach distinct is its personalization. Each treatment is custom-built for one person, using their own cells. The therapy belongs to a newer category of medicines called advanced therapy products, and they function as tailored immunotherapies—the immune system, retrained and reinforced, doing the work of chemotherapy without the systemic toxicity.
For patients with mantle cell lymphoma or acute lymphoblastic leukemia who have exhausted conventional options, the approval opens a door that was previously closed in Brazil. The disease itself is unforgiving; mantle cell lymphoma is known for its aggression and its tendency to resist treatment. The new therapy offers hope, though it comes with logistical demands—the need to send cells abroad, the specialized infrastructure required, the time involved in the manufacturing process. Still, for those who have run out of other choices, it is a path forward that did not exist before.
Citações Notáveis
The therapy reprograms the cell to recognize and combat the tumor, making the patient's own organism a treatment against cancer— Anvisa description of TECARTUS mechanism
A Conversa do Hearth Outra perspectiva sobre a história
Why does this therapy require sending cells outside Brazil? Why can't the modification happen here?
The infrastructure doesn't exist yet. These specialized centers require years to build, regulatory approval, and significant investment. Other countries have been developing CAR-T manufacturing capacity longer. Brazil is importing the service for now.
How long does the whole process take—from extraction to infusion?
The source doesn't specify, but typically it takes weeks. The patient's cells have to be collected, transported, modified in the facility, tested for safety, and shipped back. It's not a quick procedure.
Is this treatment a cure, or does the cancer come back?
The source doesn't say. It's approved for patients whose disease has returned or resisted prior treatment, but whether CAR-T itself is curative or how long remissions last isn't detailed here.
Why is this the fourth approval and not the first?
Brazil has approved other CAR-T therapies before—likely for different cancers or different companies. This is the fourth product in the category, which suggests the regulatory pathway is becoming more established.
Who can actually access this? Is it covered by public insurance?
The source doesn't address cost or insurance coverage. That's a crucial question left unanswered—approval doesn't automatically mean accessibility for most patients.